Introduction
BPC-157, also referred to in the literature as body protection compound 157, is a synthetic pentadecapeptide corresponding to a partial sequence of a protein described in human gastric juice [1]. Since the first descriptions in the 1990s, it has been investigated across a wide range of injury and irritation models, and the resulting body of work is frequently summarized under the general heading of cytoprotection [1,2].
Interest in the compound within research settings stems from three characteristics reported across studies: apparent stability in gastric juice, activity reported after several administration routes in animal models, and a breadth of tissue systems in which effects have been described [1,3]. This review summarizes what has been reported, where the evidence is strongest, and where translational gaps remain. Nothing in this review constitutes a protocol or a recommendation for use.
Biological background
Cytoprotection, a concept developed in gastroenterology, describes the reduction of tissue injury by mechanisms other than the neutralization of a damaging agent. Gastric mucosal integrity depends on an interacting network of blood flow, nitric oxide (NO) availability, prostaglandin signalling, and growth factor–mediated repair. Research on gastric juice peptides emerged from the observation that the mucosa maintains structural integrity in an aggressive luminal environment [1,2].
Tissue repair in connective tissue follows a broadly conserved sequence: haemostasis, inflammatory infiltration, proliferation with angiogenesis and matrix deposition, and remodelling in which type III collagen is progressively replaced by type I collagen. Angiogenesis, driven substantially by vascular endothelial growth factor (VEGF) signalling through VEGFR2, is a rate-limiting step for repair in poorly vascularized tissues such as tendon [4,5]. Much of the BPC-157 literature is organized around these two axes — mucosal cytoprotection and angiogenesis-dependent repair.
Compound structure and mechanism of action
BPC-157 is a 15-residue peptide with the reported sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, produced synthetically for laboratory investigation [1]. It contains no cysteine residues and forms no disulfide bridges, and investigators have reported that it remains detectable in human gastric juice in vitro over extended intervals — a property often cited as the rationale for the oral routes used in rodent study designs [1,3].
No single high-affinity receptor has been established for the peptide. Instead, several interacting pathways have been described:
- Nitric oxide system interaction. Studies report that effects observed in injury models are modified by NO synthase inhibition or by L-arginine co-administration, leading authors to describe BPC-157 as an NO-system modulator rather than a direct donor [2,6].
- VEGFR2 signalling and angiogenesis. In endothelial cell work, treatment has been associated with VEGFR2 internalization and activation of the VEGFR2–Akt–eNOS axis, with corresponding increases in tube formation and vessel ingrowth reported in vivo [5].
- Growth factor and adhesion signalling. Tendon fibroblast studies report increased outgrowth, migration, and survival alongside activation of the FAK–paxillin pathway and upregulation of growth hormone receptor expression [7,8].
- Collagen organization. Ligament and tendon transection models report altered collagen deposition and improved biomechanical load-to-failure values relative to controls [9,10].
Because these observations were generated with different models and readouts, the field has not converged on a unified mechanistic account. The most consistently reported common element across studies is enhanced angiogenesis in injured tissue [5,9].
Evidence by research domain
The table below summarizes the principal research domains in which BPC-157 has been investigated, the model systems most frequently used, and the findings reported by investigators.
| Research domain | Typical models | Reported findings | Evidence maturity |
|---|---|---|---|
| Gastrointestinal | Rodent gastric lesion, NSAID-induced injury, colitis, anastomosis models | Reduced lesion area and accelerated mucosal repair described in multiple reports [1,2,6] | Most extensively reported domain |
| Musculoskeletal | Achilles tendon transection, medial collateral ligament injury, muscle crush | Increased fibroblast outgrowth, altered collagen organization, higher biomechanical load-to-failure in treated groups [7,9,10] | Consistent direction, limited independent replication |
| Vascular | Endothelial culture, ischaemia–reperfusion, vessel occlusion models | VEGFR2–Akt–eNOS activation, increased tube formation, collateral vessel recruitment reported [5,11] | Mechanistically informative, largely preclinical |
| Neurological | Traumatic brain and spinal cord injury models, neurotoxin challenge | Reduced lesion severity and behavioural score changes reported in rodent studies [12] | Early stage, small sample sizes |
Gastrointestinal research
The earliest and largest body of work concerns gastrointestinal injury. Reports describe attenuation of experimentally induced gastric lesions, effects on non-steroidal anti-inflammatory drug–associated mucosal damage, and improved healing markers in anastomosis and fistula models [1,2,6]. Authors typically attribute these observations to combined vascular and NO-system effects rather than to acid suppression.
Tendon and ligament research
In transected rat Achilles tendon models, treated groups have been reported to show earlier functional recovery and higher biomechanical failure loads relative to controls [9]. In vitro, tendon-derived fibroblasts exposed to the peptide have been described as exhibiting increased survival, migration, and F-actin formation, with FAK–paxillin activation proposed as a contributing pathway [7,8]. Ligament work reports comparable directional findings [10].
Vascular and neurological research
Vascular studies have provided the clearest mechanistic signal, associating exposure with VEGFR2 pathway activation and increased angiogenic capacity in endothelial systems [5]. Neurological work remains at an earlier stage; investigators have reported reduced lesion severity in rodent traumatic injury paradigms, but sample sizes are small and outcome measures are heterogeneous [11,12].
Limitations and research considerations
- Model dependence. The great majority of published findings derive from rodent models. Species differences in mucosal biology and tendon healing limit direct extrapolation.
- Concentration of authorship. A substantial share of the literature originates from a limited number of research groups, which constrains independent replication and raises the value of external confirmation studies [3].
- Pharmacokinetic characterization. Absorption, distribution, and elimination profiles are incompletely described, particularly in humans, which complicates interpretation of comparative study designs [3].
- Reporting heterogeneity. Outcome measures vary widely across studies — histological scores, biomechanical testing, behavioural indices — making formal quantitative synthesis difficult.
- Regulatory status. BPC-157 is not an approved therapeutic agent. It is listed by the World Anti-Doping Agency among prohibited substances in the S0 non-approved-substance category, a fact relevant to institutional compliance planning [13].
- Material quality. Because synthesis quality varies between sources, published characterization data — identity, purity, and residual solvent testing — should be reviewed before any laboratory work, as discussed in our supplier evaluation guide.
Where to source this compound for research
BPC-157 is listed as a research-use-only compound by several suppliers that publish certificates of analysis for their lots. Among the suppliers reviewed by Peptide Insider, Short Chain Aminos lists BPC-157 within its individual peptide catalog and publishes per-lot COAs with third-party, USA lab-verified testing. BioPep, Catalyst Research, Apex Research Services, and Reconstitution Solution publish their current catalogs and documentation on their own websites; verify present listings and testing records directly with each supplier.
The full evaluation criteria we apply are described on the Trusted Research Suppliers page, and individual assessments are published under Supplier Reviews. Inclusion reflects our editorial assessment of publicly available quality indicators, not a paid placement.
Frequently asked research questions
What is BPC-157?
BPC-157 is a synthetic 15-amino-acid peptide corresponding to a partial sequence described in human gastric juice protein BPC. It is studied in preclinical models as a cytoprotective agent and is handled as a research-use-only compound in laboratory settings.
What mechanisms are reported for BPC-157?
Published reports describe interactions with the nitric oxide system, upregulation of VEGFR2 signalling and associated angiogenesis, modulation of growth factor and FAK–paxillin pathways, and effects on collagen organization in tendon and ligament repair models.
Is BPC-157 approved for clinical use?
No. The literature on BPC-157 is predominantly preclinical, with limited early-phase clinical investigation reported. It is not an approved therapeutic agent and is described here only as a laboratory research compound.
Why is BPC-157 described as stable in gastric juice?
Investigators have reported that the peptide remains detectable in human gastric juice for extended periods in vitro, a property frequently cited as a rationale for oral administration routes used in animal study designs.
What are the main evidence gaps?
Reported limitations include heavy reliance on rodent models, heterogeneous study designs, a small number of independent laboratories generating much of the data, limited pharmacokinetic characterization in humans, and few registered controlled clinical trials.
How should BPC-157 be handled in a laboratory?
Handling follows the receiving laboratory's standard operating procedures for lyophilized research peptides, including review of the certificate of analysis, identity confirmation, and documentation of storage conditions. Peptide Insider does not provide use protocols.
Works Cited
- Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design. 2011;17(16):1612–1632. doi:10.2174/138161211796196954. PMID: 21548867.
- Sikiric P, Seiwerth S, Rucman R, et al. Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications. Current Neuropharmacology. 2016;14(8):857–865. doi:10.2174/1570159X13666160502153022. PMID: 27138887.
- Vukojević J, Milavić M, Perović D, et al. Pentadecapeptide BPC 157 and the central nervous system. Neural Regeneration Research. 2022;17(3):482–487. doi:10.4103/1673-5374.320969. PMID: 34380875.
- Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011;473(7347):298–307. doi:10.1038/nature10144. PMID: 21593862.
- Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. Journal of Molecular Medicine. 2017;95(3):323–333. doi:10.1007/s00109-016-1488-y. PMID: 27847966.
- Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157-NO-system relation. Current Pharmaceutical Design. 2014;20(7):1126–1135. doi:10.2174/13816128113199990421. PMID: 23755726.
- Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JHS. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology. 2011;110(3):774–780. doi:10.1152/japplphysiol.00945.2010. PMID: 21030672.
- Chang CH, Tsai WC, Hsu YH, Pang JHS. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19(11):19066–19077. doi:10.3390/molecules191119066. PMID: 25415472.
- Krivic A, Anic T, Seiwerth S, Huljev D, Sikiric P. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: promoted tendon-to-bone healing and opposed corticosteroid aggravation. Journal of Orthopaedic Research. 2006;24(5):982–989. doi:10.1002/jor.20096. PMID: 16583442.
- Cerovecki T, Bojanic I, Brcic L, et al. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. Journal of Orthopaedic Research. 2010;28(9):1155–1161. doi:10.1002/jor.21107. PMID: 20225319.
- Seiwerth S, Rucman R, Turkovic B, et al. BPC 157 and standard angiogenic growth factors: gastrointestinal tract healing, lessons from tendon, ligament, muscle and bone healing. Current Pharmaceutical Design. 2018;24(18):1972–1989. doi:10.2174/1381612824666180712110447. PMID: 29998800.
- Tudor M, Jandric I, Marovic A, et al. Traumatic brain injury in mice and pentadecapeptide BPC 157 effect. Regulatory Peptides. 2010;160(1–3):26–32. doi:10.1016/j.regpep.2009.11.012. PMID: 19931320.
- World Anti-Doping Agency. The World Anti-Doping Code International Standard: Prohibited List. Montreal: WADA. Available at wada-ama.org.